Latest ResoTher Pharma News & Updates

See the latest news and media coverage for ResoTher Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
ResoTher Pharma

Clinical-stage biotech developing resolution therapies for cardiovascular inflammation

resotherpharma.com
Headquarters
Holte, Denmark
Founded year
2016
Company type
Private company
Number of employees
2–20
Industry
Biotechnology & Medical Research

Last updated

Latest news about ResoTher Pharma

In short: ResoTher Pharma reported positive Phase 2a results for RTP-026 and progressed toward an acquisition by Hunter Capital RTO1.

Company announcements

ResoTher Pharma

CFO chooses ResoTher Pharma

CFO of two companies selects ResoTher due to exciting funding, biotech passion, and Phase 2 trial launch. Article in Danish.

ResoTher Pharma

ResoTher Pharma receives €2.5 million EIC grant

The grant supports Phase 2a clinical study of RTP-026 for myocardial infarction. One of 47 projects selected from 648 proposals.

Unlock all announcements with a

Media coverage

BioWorld

Resother Pharma synthesizes new FPR2 agonists

Resother Pharma ApS has divulged new N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists potentially useful for the treatment of chronic inflammation.

Unlock all articles with a

Never miss news about ResoTher Pharma

Track ResoTher Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.